Lung Cancer Management

• Outstanding faculty of noted oncology experts - co-chaired by

Roy S. Herbst, MD, PhD Professor of Medicine   and Cancer Biology Department of Thoracic/Head   and Neck Medical Oncology The University of Texas   M.D. Anderson Cancer Center Houston, Texas

Corey J. Langer, MD, FACP Professor of Medicine Hematology-Oncology Division Department of Medicine University of Pennsylvania Philadelphia, Pennsylvania

• Timely and engaging information
  
• Continuous program updates, news, and announcements
  
• E-mail notification when each course becomes available
  
• Lung cancer CME program offers CME credit, CE credit or CPE credit
  
• Certificate of advanced study in lung cancer awarded upon completion of all 24 course posttests and evaluations
  

Intensive ongoing curriculum explores both non–small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC)

• NCCN Lung Cancer Treatment Guidelines
• Lung Cancer Risk Factors and Risk Assessment
• Screening and Early Detection of Lung Cancer
• Diagnostic Advances and Lung Cancer Symptoms
• Advances in Lung Cancer Staging Systems
  • Using TNM classification of malignant tumors in NSCLC (stages IA, IB, IIA, IIB, IIIA, IIIB, IV [metastatic]; early, locally advanced, and advanced tumors)
  • Using limited stage and extensive stages in SCLC
• Management of Bronchoalveolar Carcinoma (BAC)
• Current and Emerging Innovative Lung Cancer Treatment Options and Strategies
  • Surgery update
  • Chemotherapy—including newer agents, such as paclitaxel, pralatrexate, and talotrexin
  • Chemoradiation
  • Neoadjuvant and adjuvant chemotherapy
  • Consolidative chemotherapy
  • Practice-changing data on targeted therapies: vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor (EGF) inhibitors, matrix metalloprotease (MMP) inhibitors, farnesyltransferase (FT) inhibitors, multikinase inhibitors, inhibitors of Ras, HDAC, mTOR, Met, MEK, toll, and p13K, which include the following drugs, among others: gefitinib, erlotinib, bevacizumab, sunitinib, sorafenib, lonafarnib, vandetanib, cetuximab
• Personalized Treatment of Lung Cancer
• PCI in Lung Cancer
• Maintenance Therapy
• Management of Special Populations (eg, women, nonsmokers)
• Supportive Care
  

• Assess the diagnosis and staging of lung cancer utilizing knowledge of current and emerging lung cancer staging systems, tumor node metastases classification, location of tumor, performance status, and surgical resectability in order to determine appropriate stage-specific treatment approaches.
  
  
• Apply evidence-based guidelines to formulate treatment strategies for patients with early-and late-stage lung cancer.
  
  
• Evaluate the appropriate use of chemotherapeutic agents in treatment strategies for lung cancer patients that improve outcomes through knowledge of their efficacy and safety.
  
  
• Integrate targeted therapies into more-successful treatment regimens for lung cancer patients by assessing the efficacy and safety of these agents.